1
|
Kato Y, Tonomura Y, Hanafusa H, Nishimura K, Fukushima T, Ueno M. Adult Zebrafish Model for Screening Drug-Induced Kidney Injury. Toxicol Sci 2021; 174:241-253. [PMID: 32040193 DOI: 10.1093/toxsci/kfaa009] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
Drug-induced kidney injury is a serious safety issue in drug development. In this study, we evaluated the usefulness of adult zebrafish as a small in vivo system for detecting drug-induced kidney injury. We first investigated the effects of typical nephrotoxicants, gentamicin and doxorubicin, on adult zebrafish. We found that gentamicin induced renal tubular necrosis with increased lysosome and myeloid bodies, and doxorubicin caused foot process fusion of glomerular podocytes. These findings were similar to those seen in mammals, suggesting a common pathogenesis. Second, to further evaluate the performance of the model in detecting drug-induced kidney injury, adult zebrafish were treated with 28 nephrotoxicants or 14 nonnephrotoxicants for up to 4 days, euthanized 24 h after the final treatment, and examined histopathologically. Sixteen of the 28 nephrotoxicants and none of the 14 nonnephrotoxicants caused drug-induced kidney injury in zebrafish (sensitivity, 57%; specificity, 100%; positive predictive value, 100%; negative predictive value, 54%). Finally, we explored genomic biomarker candidates using kidneys isolated from gentamicin- and cisplatin-treated zebrafish using microarray analysis and identified 3 candidate genes, egr1, atf3, and fos based on increased expression levels and biological implications. The expression of these genes was upregulated dose dependently in cisplatin-treated groups and was > 25-fold higher in gentamicin-treated than in the control group. In conclusion, these results suggest that the adult zebrafish has (1) similar nephrotoxic response to those of mammals, (2) considerable feasibility as an experimental model for toxicity studies, and (3) applicability to pathological examination and genomic biomarker evaluation in drug-induced kidney injury.
Collapse
Affiliation(s)
- Yuki Kato
- Drug Safety Evaluation, Research Laboratory for Development, Shionogi and Co., Ltd., Toyonaka, Osaka 561-0825, Japan
| | - Yutaka Tonomura
- Drug Safety Evaluation, Research Laboratory for Development, Shionogi and Co., Ltd., Toyonaka, Osaka 561-0825, Japan
| | - Hiroyuki Hanafusa
- Drug Safety Evaluation, Research Laboratory for Development, Shionogi and Co., Ltd., Toyonaka, Osaka 561-0825, Japan
| | - Kyohei Nishimura
- Drug Safety Evaluation, Research Laboratory for Development, Shionogi and Co., Ltd., Toyonaka, Osaka 561-0825, Japan
| | - Tamio Fukushima
- Drug Safety Evaluation, Research Laboratory for Development, Shionogi and Co., Ltd., Toyonaka, Osaka 561-0825, Japan
| | - Motonobu Ueno
- Drug Safety Evaluation, Research Laboratory for Development, Shionogi and Co., Ltd., Toyonaka, Osaka 561-0825, Japan
| |
Collapse
|
2
|
Mrestani Y, Bretschneider B, Härtl A, Brandsch M, Neubert RHH. Influence of enhancers on the absorption and on the pharmacokinetics of cefodizime using in-vitro and in-vivo models. J Pharm Pharmacol 2010; 56:485-93. [PMID: 15099444 DOI: 10.1211/0022357023187] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
Abstract
In the development of novel antibiotics, more and more compounds have been found that cannot be absorbed orally and, therefore, must be administered intravenously or intramuscularly. Because of the obvious drawbacks of drug delivery by injection, the development of alternatives with enhanced oral bioavailability has received much attention in pharmaceutical research. Cefodizime, a novel third-generation cephalosporin with significant advantages in the parenteral treatment of common infections, was used as a model drug. Cefodizime behaves as a highly hydrophilic compound, as shown from its extremely low partition coefficient. The effect of cationic absorption enhancers (hexadecyldimethyl-benzylammonium chloride, N-hexadecylpyridinium bromide, dodecyltrimethylammonium bromide and hexadecyltrimethylammonium bromide) on the lipophilicity of cefodizime was investigated by means of the n-octanol/water system. Results showed that the counter-ions had a positive influence on the solubility of cefodizime. These results on partitioning coefficients in the n-octanol/buffer system were confirmed using an in-vitro transport model with artificial and biological membranes (Caco-2-cells). Furthermore, the physiological compatibility of the absorption enhancers was investigated using the active d-glucose transport. The pharmacokinetic profile of cefodizime was evaluated in rabbits after intraduodenal administration with and without an absorption enhancer.
Collapse
Affiliation(s)
- Yahya Mrestani
- Institute of Pharmaceutics and Biopharmaceutics, Department of Pharmacy, Martin-Luther-University Halle-Wittenberg, Wolfgang-Langenbeck-Str. 4, 06120 Halle, Germany
| | | | | | | | | |
Collapse
|